{
    "xml": "<topic id=\"PHP5378\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/gemcitabine\" basename=\"gemcitabine\" title=\"GEMCITABINE\">\n<title>GEMCITABINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1148\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/antimetabolites/gemcitabine\">Gemcitabine</xref>\n</p>\n<data name=\"vtmid\">108811008</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_699299946\" title=\"Antimetabolites\">Antimetabolites</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP72849\" outputclass=\"indicationsAndDose\" rev=\"1.20\" parent=\"/drugs/gemcitabine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">First-line treatment for locally advanced or metastatic non-small cell lung cancer (as monotherpay in elderly patients and in palliative treatment; otherwise in combination with cisplatin)</p>\n<p outputclass=\"therapeuticIndication\">Treatment of locally advanced or metastatic pancreatic cancer</p>\n<p outputclass=\"therapeuticIndication\">Treatment of advanced or metastatic bladder cancer (in combination with cisplatin)</p>\n<p outputclass=\"therapeuticIndication\">Treatment of locally advanced or metastatic epithelial ovarian cancer which has relapsed after a recurrence-free interval of at least 6 months following previous platinum-based therapy (in combination with carboplatin)</p>\n<p outputclass=\"therapeuticIndication\">Treatment of metastatic breast cancer which has relapsed after previous chemotherapy including an anthracycline (in combination with paclitaxel)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult local protocol).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72839\" outputclass=\"interactions\" rev=\"1.8\" parent=\"/drugs/gemcitabine\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (gemcitabine).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72776\" outputclass=\"sideEffects\" rev=\"1.16\" parent=\"/drugs/gemcitabine\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Haemolytic uraemic syndrome</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression</ph>; <ph outputclass=\"sideEffect\">extravasation</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">influenza-like symptoms</ph>; <ph outputclass=\"sideEffect\">microangiopathic haemolytic anaemia</ph>; <ph outputclass=\"sideEffect\">mild gastro-intestinal side-effects</ph>; <ph outputclass=\"sideEffect\">musculoskeletal pain</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">pulmonary toxicity</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">renal impairment</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Microangiopathic haemolytic anaemia</p>\n<p>Gemcitabine should be discontinued if signs of microangiopathic haemolytic anaemia occur.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72896\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/gemcitabine\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given to men and women before cytotoxic therapy begins; manufacturer advises effective contraception during treatment. Men must avoid fathering a child during and for 6 months after treatment.</p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72824\" outputclass=\"pregnancy\" parent=\"/drugs/gemcitabine\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid (teratogenic in <i>animal</i> studies).</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72920\" outputclass=\"breastFeeding\" parent=\"/drugs/gemcitabine\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Discontinue breast-feeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72859\" outputclass=\"hepaticImpairment\" parent=\"/drugs/gemcitabine\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72804\" outputclass=\"renalImpairment\" parent=\"/drugs/gemcitabine\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72742\" outputclass=\"nationalFunding\" rev=\"1.20\" parent=\"/drugs/gemcitabine\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA25</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Gemcitabine for the treatment of pancreatic cancer (May 2001)</p>\r\n<p>Gemcitabine is an option for first-line chemotherapy for patients with advanced or metastatic adenocarcinoma of the pancreas and a Karnofsky score of at least 50 [Karnofsky score is a measure of the ability to perform ordinary tasks].</p>\r\n<p>Gemcitabine is not recommended for patients who can have potentially curative surgery. There is insufficient evidence about its use for second-line treatment of pancreatic adenocarcinoma.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA25\">www.nice.org.uk/TA25</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA116</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Gemcitabine for the treatment of metastatic breast cancer (January 2007)</p>\r\n<p>Gemcitabine, in combination with paclitaxel, is an option for the treatment of metastatic breast cancer <b>only</b> when docetaxel monotherapy or docetaxel plus capecitabine are also considered appropriate.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA116\">www.nice.org.uk/TA116</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA285</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Bevacizumab in combination with gemcitabine and carboplatin for the treatment of the first recurrence of platinum-sensitive advanced ovarian cancer (May 2013)</p>\r\n<p>Bevacizumab in combination with gemcitabine and carboplatin is <b>not</b> recommended within its marketing authorisation, that is, for the treatment of the first recurrence of platinum-sensitive advanced ovarian cancer (including fallopian tube and primary peritoneal cancer) that has not been previously treated with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor-targeted agents.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA285\">www.nice.org.uk/TA285</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (November 2006) that gemcitabine is accepted for restricted use for the treatment of metastatic breast cancer, which has relapsed following previous chemotherapy including an anthracycline (unless contra-indicated).</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP5378-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/gemcitabine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76063\" title=\"Solution for infusion\" namespace=\"/drugs/gemcitabine/solution-for-infusion\">Solution for infusion</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76058\" title=\"Powder for solution for infusion\" namespace=\"/drugs/gemcitabine/powder-for-solution-for-infusion\">Powder for solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1148\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/antimetabolites/gemcitabine\" title=\"Gemcitabine\" count=\"1\" rel=\"link\">Gemcitabine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76063\" namespace=\"/drugs/gemcitabine/solution-for-infusion\" title=\"Solution for infusion\" count=\"1\" rel=\"link\">Solution for infusion</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76058\" namespace=\"/drugs/gemcitabine/powder-for-solution-for-infusion\" title=\"Powder for solution for infusion\" count=\"1\" rel=\"link\">Powder for solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP5378",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/gemcitabine",
    "basename": "gemcitabine",
    "title": "GEMCITABINE",
    "interactants": [
        {
            "id": "bnf_int_1148",
            "label": "Gemcitabine"
        }
    ],
    "vtmid": "108811008",
    "drugClassification": [
        "Antimetabolites"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "First-line treatment for locally advanced or metastatic non-small cell lung cancer (as monotherpay in elderly patients and in palliative treatment; otherwise in combination with cisplatin)",
                        "html": "First-line treatment for locally advanced or metastatic non-small cell lung cancer (as monotherpay in elderly patients and in palliative treatment; otherwise in combination with cisplatin)"
                    },
                    {
                        "textContent": "Treatment of locally advanced or metastatic pancreatic cancer",
                        "html": "Treatment of locally advanced or metastatic pancreatic cancer"
                    },
                    {
                        "textContent": "Treatment of advanced or metastatic bladder cancer (in combination with cisplatin)",
                        "html": "Treatment of advanced or metastatic bladder cancer (in combination with cisplatin)"
                    },
                    {
                        "textContent": "Treatment of locally advanced or metastatic epithelial ovarian cancer which has relapsed after a recurrence-free interval of at least 6 months following previous platinum-based therapy (in combination with carboplatin)",
                        "html": "Treatment of locally advanced or metastatic epithelial ovarian cancer which has relapsed after a recurrence-free interval of at least 6 months following previous platinum-based therapy (in combination with carboplatin)"
                    },
                    {
                        "textContent": "Treatment of metastatic breast cancer which has relapsed after previous chemotherapy including an anthracycline (in combination with paclitaxel)",
                        "html": "Treatment of metastatic breast cancer which has relapsed after previous chemotherapy including an anthracycline (in combination with paclitaxel)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "(consult local protocol).",
                        "html": "<p>(consult local protocol).</p>"
                    }
                ]
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (gemcitabine).",
                "html": "<p>Appendix 1 (gemcitabine).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Haemolytic uraemic syndrome",
                        "html": "Haemolytic uraemic syndrome",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression",
                        "html": "bone-marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "extravasation",
                        "html": "extravasation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "influenza-like symptoms",
                        "html": "influenza-like symptoms",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "microangiopathic haemolytic anaemia",
                        "html": "microangiopathic haemolytic anaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "mild gastro-intestinal side-effects",
                        "html": "mild gastro-intestinal side-effects",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "musculoskeletal pain",
                        "html": "musculoskeletal pain",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pulmonary toxicity",
                        "html": "pulmonary toxicity",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "renal impairment",
                        "html": "renal impairment",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Microangiopathic haemolytic anaemia",
                "textContent": "Gemcitabine should be discontinued if signs of microangiopathic haemolytic anaemia occur.",
                "html": "<p>Gemcitabine should be discontinued if signs of microangiopathic haemolytic anaemia occur.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given to men and women before cytotoxic therapy begins; manufacturer advises effective contraception during treatment. Men must avoid fathering a child during and for 6 months after treatment.\n\nRegimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins; manufacturer advises effective contraception during treatment. Men must avoid fathering a child during and for 6 months after treatment.</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid (teratogenic in animal studies).\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Avoid (teratogenic in <i>animal</i> studies).</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Discontinue breast-feeding.",
                "html": "<p>Discontinue breast-feeding.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution.",
                "html": "<p>Manufacturer advises caution.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution.",
                "html": "<p>Manufacturer advises caution.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA25",
                        "label": "www.nice.org.uk/TA25"
                    }
                ],
                "fundingIdentifier": "NICE TA25",
                "textContent": "Gemcitabine for the treatment of pancreatic cancer (May 2001) Gemcitabine is an option for first-line chemotherapy for patients with advanced or metastatic adenocarcinoma of the pancreas and a Karnofsky score of at least 50 [Karnofsky score is a measure of the ability to perform ordinary tasks]. Gemcitabine is not recommended for patients who can have potentially curative surgery. There is insufficient evidence about its use for second-line treatment of pancreatic adenocarcinoma.\n\nwww.nice.org.uk/TA25",
                "html": "<p outputclass=\"title\">Gemcitabine for the treatment of pancreatic cancer (May 2001)</p> <p>Gemcitabine is an option for first-line chemotherapy for patients with advanced or metastatic adenocarcinoma of the pancreas and a Karnofsky score of at least 50 [Karnofsky score is a measure of the ability to perform ordinary tasks].</p> <p>Gemcitabine is not recommended for patients who can have potentially curative surgery. There is insufficient evidence about its use for second-line treatment of pancreatic adenocarcinoma.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA25\">www.nice.org.uk/TA25</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA116",
                        "label": "www.nice.org.uk/TA116"
                    }
                ],
                "fundingIdentifier": "NICE TA116",
                "textContent": "Gemcitabine for the treatment of metastatic breast cancer (January 2007) Gemcitabine, in combination with paclitaxel, is an option for the treatment of metastatic breast cancer only when docetaxel monotherapy or docetaxel plus capecitabine are also considered appropriate.\n\nwww.nice.org.uk/TA116",
                "html": "<p outputclass=\"title\">Gemcitabine for the treatment of metastatic breast cancer (January 2007)</p> <p>Gemcitabine, in combination with paclitaxel, is an option for the treatment of metastatic breast cancer <b>only</b> when docetaxel monotherapy or docetaxel plus capecitabine are also considered appropriate.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA116\">www.nice.org.uk/TA116</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA285",
                        "label": "www.nice.org.uk/TA285"
                    }
                ],
                "fundingIdentifier": "NICE TA285",
                "textContent": "Bevacizumab in combination with gemcitabine and carboplatin for the treatment of the first recurrence of platinum-sensitive advanced ovarian cancer (May 2013) Bevacizumab in combination with gemcitabine and carboplatin is not recommended within its marketing authorisation, that is, for the treatment of the first recurrence of platinum-sensitive advanced ovarian cancer (including fallopian tube and primary peritoneal cancer) that has not been previously treated with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor-targeted agents.\n\nwww.nice.org.uk/TA285",
                "html": "<p outputclass=\"title\">Bevacizumab in combination with gemcitabine and carboplatin for the treatment of the first recurrence of platinum-sensitive advanced ovarian cancer (May 2013)</p> <p>Bevacizumab in combination with gemcitabine and carboplatin is <b>not</b> recommended within its marketing authorisation, that is, for the treatment of the first recurrence of platinum-sensitive advanced ovarian cancer (including fallopian tube and primary peritoneal cancer) that has not been previously treated with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor-targeted agents.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA285\">www.nice.org.uk/TA285</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76063",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76058",
                "label": "Powder for solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1148",
                "label": "Gemcitabine",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76063",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76058",
                "label": "Powder for solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}